Sernova Biotherapeutics Inc · TSX:SVA
Sernova Biotherapeutics — Sernova — Investor Presentation (2015)
19 slides from Sernova Biotherapeutics's investor presentation, 2015
Slide 1: Investor Presentation 2015
Investor Presentation 2015 Improving the Quality of Life for Patients with Chronic Disease TSX-V: SVA OTCQB: SEOVF
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation may contain forward looking statements. Forward looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. The
Slide 3: Sernova is a Canadian based, clinical stage, regenerative medicine company
3 Sernova is a Canadian based, clinical stage, regenerative medicine therapeutics company Sernova has developed a scalable, implantable medical device, The Cell Pouch, for the survival and function of therapeutic, immune protected cells Our platform addresses the unmet needs of patients suffering se
Slide 4: Key Management
4 Key Management Dr. Philip Toleikis, PRESIDENT AND CEO Previous Angiotech Head of R&D (reached $2.0B market cap; Board of Directors drug/device combinations) Frank Holler, CHAIRMAN Frank Holler Co-Founder Angiotech & ID Biomedical ($1.6BM Exit to GSK), Jeffrey Bacha Xenon Pharma James Parsons Ralph
Slide 5: Our Therapeutic System
Our Therapeutic System The Total Regenerative Medicine 5 Solution 1 Cell Pouch™ An implantable medical device for therapeutic cells placed under the skin Proven safety in humans Cell Therapeutic Pouch™ Cells 2 Therapeutic Cells Cells that produce and release missing (or needed) proteins or hormone
Slide 6: Diabetes Market & Opportunity
Diabetes Market 6 & Opportunity The Cell Pouch delivery system offers a potential for treatments across multiple chronic diseases, primarily Diabetes (Type 1 and 2) and Haemophlia Diabetes Insulin therapy: 37% (9M US/34M Asia) Epidemiology Sernova patented countries: 25M patients) 10% 27% Diabetes s
Slide 7: Sernova Product #1: Diabetes
Sernova Product #1: Diabetes 7 Performs as an artificial pancreas – eliminates needles, injectables, pumps ➺ Patient population: Insulin injections, insulin pumps, Edmonton Protocol ➺ 9M North America, 35-40M Worldwide ➺ Sernova product goals: Reduce hypoglycemia unawareness; reduce exogenous insuli
Slide 8: Sernova Product #2: Haemophilia
Sernova Product #2: Haemophilia 8 $5B/yr Orphan indication for patients whose blood is missing a critical clotting agent ➺ Patient population: Haemophilia A ≈20,000 NA/EU ➺ Current products: 3X weekly infusions of Factor VIII ($200k/yr) ➺ Sernova’s Product: Therapeutic cells within the Cell Pouch wh
Slide 9: Current State of the Art
Current State of the Art 9 Insulin Pumps – a huge unmet medical need Components, clockwise include: ➺ Insulin ➺ Insulin pump reservoir ➺ AAA battery ➺ Insulin pump infusion set ➺ Emergency glucagon kit ➺ Insulin pump ➺ Test strips ➺ Lancets Typical Approximate Annual Cost (US): with insurance $4,000
Slide 10: Diabetes Treatment Overview
10 Diabetes Treatment Overview ➺ Main Problem: Outdated Treatment Sernova’s Goal is Methods for the Cell Pouch to be transplanted ➺ What people are using is inadequate with advanced • Insulin injections, pumps, medications, etc., or cells such as • Transplant of donor islets into the portal vein ins
Slide 11: Preclinical Proof of Concept
Preclinical Proof of Concept Cell Pouch™ Islet Transplant in Small 11 Animals (A) Severely diabetic animal. Cell Pouch™ & Photograph of islets within the Cell therapeutic cells transplanted. Achieve normal Pouch™ after 100 days. glucose level for 100 days and then device Red = insulin, Green = blood
Slide 12: Preclinical Efficacy: Cell Pouch
Preclinical Efficacy: Cell Pouch™ Cell Pouch™ Large Animal Islet Transplant Study 12 Diabetes induction Cell (STZ) Cell Pouch™ Islet Pouch™ removal Pancreatectomy Transplant implant D ia b e tic ( n = 2 ) 4-8 weeks 1 day 4-7 days 8-12 weeks 1 week Cell Pouch™ developed tissue Sustained large animal
Slide 13: Preclinical Efficacy: Cell Pouch
Preclinical Efficacy: Cell Pouch™ 12 Weeks Post Cell Pouch™ and 13 Islet Transplant Islets showing insulin (red) and supporting blood vessels (green) Insulin vWF Healthy Islets Nuclei in the Cell Insulin Pouch™ vWF (purple); Micro-vessels (red arrows) Sernova Corp Sernova Corp Sernova Corp Sernova C
Slide 14: Insulin Independence Proven in Diabetic Animals
Insulin Independence Proven in Diabetic Animals 14 200 islets/mouse Glucose levels rise upon Cell Pouch™ removal ➺ Independent 3rd party assessment proves 95% insulin independence in diabetic animals ➺ Proven healthy islets with strong insulin staining & microvessels ➺ Efficacy using the marginal is
Slide 15: Clinical Study: Proof of Concept
Clinical Study: Proof of Concept 15 ➺ Phase I/II Clinical Study conducted in subjects with severe diabetes ➺ Measures of Cell Pouch™ and cell safety are demonstrated ➻ Islets housed within a natural tissue matrix ➻ Islets are well vascularized ➻ Safety standards were successfully met ➻ Islets show e
Slide 16: Diabetes Value Drivers?
Diabetes Value Drivers? 16 ➺ Donor islets results advance proof of concept and secures Cell Pouch as a viable technology ➺ Unlimited supply of cells could treat the current 35-40M diabetic population ➻ Sernova is focused on evaluating glucose responsive stem cell technologies ➻ Sernova is evaluating
Slide 17: Why Invest in Sernova?
17 Why Invest in Sernova? ➺ Sernova has advanced the novel Cell Pouch technologies over the past 6 years and has a robust international patent portfolio which includes U.S. and foreign patents – key to pharma licensing deals ➺ Key preclinical safety and efficacy demonstrated with islet therapy treat
Slide 18: Sernova: Potential Upside/3-12 mth Roadmap
Sernova: Potential Upside/3-12 mth Roadmap 18 deal zone ~Partnerships Time= 6mths-1y M/C Range>$150M 2009-12 $0.30/share Licensing Immediate Potential – 3-5x M/C>$40M seller = bio Return buyer = pharma With Efficacy (> 10X) With Partner ($1.50-2.00) pI/II pII pIII sales academic pre-clinical Clinica
Slide 19: Contact
19 Contact www.sernova.com General Inquiries Investor Relations Business 1-877-299-4603 Development Ray Matthews info@sernova.com +1-604-818-7778 Philip Toleikis 114 - 700 Collip Circle ray@raymatthews.ca +1-604-961-2939 London, ON N6G 4X8 info@sernova.com